Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors - Related Studies

Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors

This study is currently recruiting participants.

Study NCT00003839. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Cancer
		Carcinoma of Unknown Primary
		Colorectal Cancer
		Esophageal Cancer
		Gallbladder Cancer
		Gastric Cancer
		Liver Cancer
		Lung Cancer
		Pancreatic Cancer
		Prostate Cancer
		Sarcoma

2	Additional conditions recognized in this trial
		Breast Neoplasms
		Carcinoma
		Colorectal Neoplasms
		Esophageal Diseases
		Esophageal Neoplasms
		Gallbladder Neoplasms
		Liver Neoplasms
		Lung Neoplasms
		Neoplasms, Unknown Primary
		Pancreatic Neoplasms
		Prostatic Neoplasms
		Stomach Neoplasms

3	More general conditions related to this trial
		Biliary Tract Diseases
		Biliary Tract Neoplasms
		Breast Diseases
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gallbladder Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Genital Diseases, Male
		Genital Neoplasms, Male
		Head and Neck Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Liver Diseases
		Lung Diseases
		Neoplasm Metastasis
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Glandular and Epithelial
		Neoplastic Processes
		Pancreatic Diseases
		Pathologic Processes
		Prostatic Diseases
		Rectal Diseases
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Skin Diseases
		Stomach Diseases
		Thoracic Neoplasms
		Urogenital Neoplasms

4	Interventions listed in this trial
		anti-thymocyte globulin
		cyclophosphamide
		cyclosporine
		fludarabine phosphate
		therapeutic allogeneic lymphocytes

5	Additional drug interventions recognized in this trial
		Antilymphocyte Serum
		Cyclosporins
		Fludarabine
		Fludarabine monophosphate

6	More general drug interventions related to this trial
		Alkylating Agents
		Anti-Infective Agents
		Antifungal Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antirheumatic Agents
		Dermatologic Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		National Heart, Lung, and Blood Institute (NHLBI)